-Beating Tomorrow-

Greetings

 Since the discovery of iPS cells in 2006, the field of stem cell research has developed greatly.  However in order for iPS cells to be put to practical use in society and to save lives, there are still many obsticals to overcome. While being encouraged by the expectations of many people, through trial and error for the past decade, we have continued to make discoveries and developing new techniques. Still, in order to put our research findings into practical use, we believe it is necessary to find the balance between the effectiveness, productivity and stability of techniques. With these goals in mind, we aim to become a research development enterprise which is able to match practical applications with the social economy.

 

 The heart is an organ directly linked to life, and new therapies and treatments are anticipated for various heart diseases. However, the use of drugs such as anticancer drugs, antibacterial drugs and analgesics, sometimes needs to be restricted due to side effects (cardiotoxicity) to the heart. The cost and time for the evaluation of these side effects including cardiotoxicity, is also a problem. It is currently greatly anticipated that progress in the practical application of iPS cells, will enables the development of new drugs and treatments to solve this problem.

 

 We are convinced that the time will come where the "cell" will greatly change the world, and step by step  the benefits of this cell technology will spread not only to some people, but to everyone.

Myoridge cardiomyocytes

Publications
  •  Yuji Shiba, Toshihito Gomibuchi, Tatsuichiro Seto, Yuko Wada, Hajime Ichimura, Yuki Tanaka, Tatsuki Ogasawara, Kenji Okada, Naoko Shiba, Kengo Sakamoto, Daisuke Ido, Takashi Shiina, Masamichi Ohkura, Junichi Nakai, Narumi Uno, Yasuhiro Kazuki, Mitsuo Oshimura, Itsunari Minami, Uichi Ikeda, MHC-matched allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates non-human primate hearts. Nature. 2016 Oct 28. 
  • Kadota S, Minami I, et al., Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. European Heart Journal. 2013 April 34. 
  • Minami I, et al., A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Reports, 2012 Nov 29.
  •  Yuji Shiba, Toshihito Gomibuchi, Tatsuichiro Seto, Yuko Wada, Hajime Ichimura, Yuki Tanaka, Tatsuki Ogasawara, Kenji Okada, Naoko Shiba, Kengo Sakamoto, Daisuke Ido, Takashi Shiina, Masamichi Ohkura, Junichi Nakai, Narumi Uno, Yasuhiro Kazuki, Mitsuo Oshimura, Itsunari Minami, Uichi Ikeda, MHC-matched allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates non-human primate hearts. Nature. 2016 Oct 28. 
Members
Naohiro Makita
CEO
Shungo Adachi
COO
Shinichi Sueta
CTO
Itsunari Minami
Technical advisor
Itsunari Minami
Technical advisor
About Us
Name Myoridge Co. Ltd.
President Naohiro Makita
Establishment August 10th, 2016
Adress

15 Shimogamomorimoto-cho, Sakyo-ku, Kyoto, 606-0805, Japan

Establishment August 10th, 2016
Contact Us
For business development inquiry, please contact our COO, Shungo Adachi.
Mail : adachi@myoridge.co.jp
Phone : +81-80-4351-8120